Adaptive Biotechnologies (ADPT) Earnings Date & Reports

Key Takeaways

• Adaptive Biotechnologies reported third quarter 2026 revenue of $83.9 million, up 39% year over year and well above the roughly $71.6 million consensus estimate.
• Earnings per share (EPS) came in at $0.02, a sharp swing above the consensus expectation of a $0.10 loss, marking a rare GAAP-profitable quarter for the company.
• clonoSEQ test volume grew 46% year over year to 39,587 tests, while the MRD (Minimal Residual Disease) business generated $72.6 million in revenue.
• Total company adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) turned positive at $14.3 million, with the MRD segment contributing $15.1 million.
• Management raised full-year 2026 MRD revenue guidance to $276 million to $286 million, up from the prior $268 million to $278 million range.
• For additional context on this ticker, you can explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To discover data-driven trading ideas across the market, explore Trending AI Robots.

Earnings Context and Why It Matters

Adaptive Biotechnologies is a commercial-stage biotechnology company built around the clonoSEQ assay, which detects and monitors MRD (Minimal Residual Disease) in blood cancers using next-generation sequencing (NGS). For several quarters, investors have watched the company narrow its losses while accelerating test volumes, and the third quarter represented a potential inflection point. Because Adaptive has historically burned cash while scaling its clinical and biopharmaceutical businesses, this report was closely watched as a test of whether revenue growth could finally translate into company-wide profitability. The results carry broader significance for the MRD diagnostics market, where reimbursement trends, guideline updates, and drug-development demand are all shaping long-term adoption.

Reported Results

Adaptive Biotechnologies reported third quarter 2026 revenue of $83.9 million, a 39% increase from the prior-year period and ahead of the consensus estimate of roughly $71.6 million. MRD revenue reached $72.6 million, while Immune Medicine revenue contributed $11.3 million, primarily reflecting the company's target discovery agreement with Pfizer. clonoSEQ test volume climbed 46% year over year to 39,587 tests.

On the bottom line, the company posted GAAP (Generally Accepted Accounting Principles) net income of $2.8 million, or $0.02 per share, compared with consensus expectations of a $0.10 loss per share. This marks a notable step toward profitability for a business that had been consistently unprofitable. Total company adjusted EBITDA was positive at $14.3 million, with the MRD segment generating $15.1 million in adjusted EBITDA, up from $7 million a year earlier. Sequencing gross margin improved to 73%, up from 66%.

Management raised its full-year 2026 MRD revenue guidance to $276 million to $286 million, up from the previous $268 million to $278 million range, and now expects full-year operating expenses of approximately $350 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for investors who want to act on earnings-related developments and broader market signals with greater speed and confidence.

Market Reaction and Investor Sentiment

Heading into the report, sentiment toward Adaptive Biotechnologies had been cautiously optimistic as the company repeatedly beat estimates in prior quarters while steadily narrowing losses. The third quarter's combination of a top-line beat, positive EPS, and company-wide adjusted EBITDA profitability represented a stronger result than many analysts had modeled, and the raised full-year guidance reinforced confidence in the growth trajectory. Key drivers behind investor attention included accelerating clonoSEQ test volumes, expanding adoption of blood-based testing, and progress in the MRD pharmaceutical business. The primary questions now center on whether the company can sustain profitability in the fourth quarter and beyond, given that management cautioned it does not currently anticipate GAAP net income or positive EPS for the fourth quarter or the full year.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether Adaptive Biotechnologies can convert its momentum into durable, company-wide profitability. Management has signaled that the fourth quarter may not repeat the third quarter's GAAP profit, so the path of adjusted EBITDA and operating leverage will be a central theme.

Several specific catalysts are worth monitoring. First, the company's maintenance bundle submission is now under review with MolDx, and progress on reimbursement expansion could meaningfully influence future clinical testing revenue and average selling prices. Second, the MRD pharmaceutical business continues to grow, with backlog of approximately $270 million, up 34% year over year, and 191 active studies providing visibility into future sequencing revenue.

Third, the shift toward blood-based testing and increased community-setting adoption remain important volume drivers, as they lower barriers to ordering and support more frequent serial monitoring. Finally, investors should watch the company's cash position and expense discipline, particularly as it weighs strategic options for its Immune Medicine segment. These factors, rather than any single quarterly figure, are likely to shape the company's narrative over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations